Cargando…

Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice

Mutations in BRCA genes are the leading cause of hereditary breast cancer. Current options to prevent cancer in these high-risk patients, such as anti-estrogen drugs and radical mastectomy, are limited by lack of efficacy, undesirable toxicities, or physical and emotional challenges. We have previou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Di, Singh, Bijay, Moerland, Jessica, Mitchell, Owen, Lockwood, Lizbeth, Carapellucci, Sarah, Sridhar, Srinivas, Liby, Karen T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806744/ https://www.ncbi.nlm.nih.gov/pubmed/33441637 http://dx.doi.org/10.1038/s41598-020-79663-7

Ejemplares similares

A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice
por: Zhang, Di, et al.
Publicado: (2019)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer
por: Belz, Jodi E., et al.
Publicado: (2017)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
por: Li, Jiaguo, et al.
Publicado: (2020)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
por: Zhou, Dong, et al.
Publicado: (2021)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer
por: Leal, Ana S., et al.
Publicado: (2021)

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
por: Herriott, Ashleigh, et al.
Publicado: (2015)

The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer
por: Moerland, Jessica A., et al.
Publicado: (2020)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
por: Engert, Florian, et al.
Publicado: (2016)

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
por: Lakomy, David S., et al.
Publicado: (2019)

Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
por: Baldwin, Paige, et al.
Publicado: (2019)

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
por: Yap, Timothy A., et al.
Publicado: (2022)

The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer
por: Reich, Lyndsey A., et al.
Publicado: (2022)

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
por: Liu, Xuan, et al.
Publicado: (2022)

Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy
por: Polyanskaya, Elizaveta, et al.
Publicado: (2023)

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2020)

Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model
por: Baldwin, Paige, et al.
Publicado: (2019)

Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models
por: Leal, Ana S., et al.
Publicado: (2019)

Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
por: Naito, Yoichi, et al.
Publicado: (2021)

Reduced canine BRCA2 expression levels in mammary gland tumors
por: Yoshikawa, Yasunaga, et al.
Publicado: (2015)

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
por: Blum, Joanne L., et al.
Publicado: (2022)

Timely Genetic Testing and Therapy Management in Patients With gBRCA-Mutated Metastatic Breast Cancer Receiving Talazoparib
por: Martinez, Ashley, et al.
Publicado: (2022)

The Infrared Radiation Temperature Characteristic of Acupoints of Mammary Gland Hyperplasia Patients
por: Zheng, Juanjuan, et al.
Publicado: (2013)

Effects of BRCA1 Transgene Expression on Murine Mammary Gland Development and Mutagen-Induced Mammary Neoplasia
por: Hoshino, Arichika, et al.
Publicado: (2007)

Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation
por: Lesueur, Paul, et al.
Publicado: (2018)

A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
por: Gruber, Joshua J., et al.
Publicado: (2022)

Role of the BRCA1 gene in stem cells and treatment of mammary gland cancer
por: Rassi, H
Publicado: (2009)

Acupuncture for mammary gland hyperplasia: A Bayesian network meta-analysis protocol
por: Xiong, Jun, et al.
Publicado: (2020)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours
por: Ordonez, Liliana D., et al.
Publicado: (2019)

Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019)

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity
por: Litton, J. K., et al.
Publicado: (2017)

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature
por: Albarrán, Víctor, et al.
Publicado: (2023)

XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA
por: Hirota, Kouji, et al.
Publicado: (2022)

Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC–MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies
por: Attwa, Mohamed W, et al.
Publicado: (2020)

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial
por: Rodon Ahnert, J., et al.
Publicado: (2023)

Mechanisms of single herbs and herbal pairs in the treatment of mammary gland hyperplasia: An integrated review()
por: Yang, Xujie, et al.
Publicado: (2023)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
por: Ding, Xia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6qs0uj7ejuqonhbduqf3gddgk6